GEN-1 Immunotherapy Continues to Show Promise in Newly Diagnosed Advanced Ovarian Cancer Patients

GEN-1 Immunotherapy Continues to Show Promise in Newly Diagnosed Advanced Ovarian Cancer Patients
Combining the DNA-based immunotherapy GEN-1 with standard of care neoadjuvant chemotherapy continues to show promise in patients with newly-diagnosed advanced ovarian cancer who will undergo interval debulking surgery, according to the most recent data of the OVATION study. In the first 12 patients dosed, which include patients from the fourth and final cohort, the combination

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *